Nature Cancer(@NatureCancer) 's Twitter Profile Photo

💫ONLINE NOW Nature Cancer “c-Kit signaling potentiates CAR T cell efficacy in solid tumors by CD28- and IL-2-independent co-stimulation” by & Co.


Read it here👇
nature.com/articles/s4301…
rdcu.be/dfFH0

account_circle
IDDB Editors(@EditorsIddb) 's Twitter Profile Photo

New review article in : 'Conception and Configuration of Biobank of CART Biospecimen Set for Pediatric Research' by Drs Wang et al.
doi.org/10.36401/IDDB-…

Zisis Kozlakidis PAIMAN Paiman

New review article in #IDDB: 'Conception and Configuration of Biobank of CART Biospecimen Set for Pediatric Research' by Drs Wang et al. 
doi.org/10.36401/IDDB-…
#CARTcells #Biospecimen
@ZKozlakidis  @BeheshtaPaiman
account_circle
Amar Gajjar(@DrAmarGajjar) 's Twitter Profile Photo

Translating therapy to brain tumors is hard due to the lack of persistence of s. Postdoc Meghan Duke shows how the persistence of s against G3 medulloblastomas can be improved via epigenetic regulation of exhaustion. tinyurl.com/2hd2ezmh

Translating #CARTcell therapy to brain tumors is hard due to the lack of persistence of #CARTcells. Postdoc Meghan Duke shows how the persistence of #CARTcells against G3 medulloblastomas can be improved via epigenetic regulation of exhaustion. tinyurl.com/2hd2ezmh #PedsSNO
account_circle
Sara Elizabeth Siegler(@sesiegler) 's Twitter Profile Photo

If you change the manufacturing process early on relative to an existing CAR, you need a new IND as evidenced by the two aforementioned case studies (Tecartus/Yescarta and YTB323/Kymriah). $NVS

account_circle
Nucleus Plus: CAR T(@Emerging_CAR_T) 's Twitter Profile Photo

Nucleus Plus deep dives into relevant topics to the & community. Check out content related to emerging CAR T therapies, treatments, research & more. Read the latest in : ow.ly/pFTl50OR5fJ cells

Nucleus Plus deep dives into relevant topics to the #transplantation & #cellulartherapy community. Check out content related to emerging CAR T therapies, treatments, research & more. Read the latest in #CART: ow.ly/pFTl50OR5fJ #CARTcells
account_circle
John De Vos(@_jdevos_) 's Twitter Profile Photo

‼️Take a look. This week, two trials and one trial, looking for new targets: CD7 (T-ALL), GD2 (neuroblastoma) and gp120 (HIV). ⤵️

account_circle
immixBio (NASDAQ:IMMX)(@immixBio) 's Twitter Profile Photo

NXC-201 Clinical Highlights for Patients with :

- No neurotoxicity observed
- Outpatient CAR-T potential

More highlights in our corporate presentation: bit.ly/41YTjRK $IMMX

account_circle
immixBio (NASDAQ:IMMX)(@immixBio) 's Twitter Profile Photo

NXC-201 is a next-generation chimeric antigen receptor (CAR) T-cell (CAR-T) produced by our N-GENIUS platform targeting B-cell maturation antigen (BCMA).

Learn more about NXC-201’s key characteristics: bit.ly/41YTjRK $IMMX

account_circle
Barbara Willekens(@drBWillekens) 's Twitter Profile Photo

And the CAR-T cells are entering in neurological disorders. Very interesting approach and without prior lymphodepletion.
raffaellagreco sciencedirect.com/science/articl…

account_circle
Pepper(@wearpepper) 's Twitter Profile Photo

✨GET 20% OFF✨ the bra reinvented for small boobs with code SOL20. No more cup gaps, awkward padding or digging wires. Just natural, flattering lift and boob-hugging comfort ☁️

account_circle
Nucleus Plus: CAR T(@Emerging_CAR_T) 's Twitter Profile Photo

New research shows technical and logistical stumbling blocks limit ex vivo engineering of (which have profound promise as a therapy for B-cell malignancies) but in vivo generation may offer an effective work-around. Read more on Nucleus Plus: ow.ly/kv3Q50OO9Mi

New research shows technical and logistical stumbling blocks limit ex vivo engineering of #CARTcells (which have profound promise as a therapy for B-cell malignancies) but in vivo generation may offer an effective work-around. Read more on Nucleus Plus: ow.ly/kv3Q50OO9Mi
account_circle
Hemalatha Rangarajan MD https(@hmgcoa2) 's Twitter Profile Photo

HLH-like toxicities predict poor survival after the use of tisagenlecleucel in children and young adults with B-ALL, data from n=185 CAYA pts..from Pediatric Real world car consortium ashpublications.org/bloodadvances/…

account_circle
etf.com(@etfcom) 's Twitter Profile Photo

Artificial intelligence is changing our world. Check out how Qraft AI ETFs applies AI to momentum investing in their 4-year-old fund AMOM.

account_circle
Christian Capitini(@CapitiniMD) 's Twitter Profile Photo

We are hiring a Pediatric Clinical Nurse Specialist to support the great nurses in our cancer and blood disorders program. Opportunities for enhancing QI and education in UW Health Apply here: eimy.fa.us6.oraclecloud.com/hcmUI/Candidat…

account_circle
John De Vos(@_jdevos_) 's Twitter Profile Photo

Another trial: RNA anti-BCMA CART to treat the autoimmune Myasthenia gravis disease. Low toxicity, significant efficacy.
Of note, the RNA strategy comes with limited side effects compared to DNA CART: no cytokine release syndrome nor neurotoxicity.

Another #CARTCells trial: RNA anti-BCMA CART to treat the autoimmune Myasthenia gravis disease. Low toxicity, significant efficacy. 
Of note, the RNA strategy comes with limited side effects compared to DNA CART: no cytokine release syndrome nor neurotoxicity.
account_circle
Bluecord(@BluecordHQ) 's Twitter Profile Photo

The field of cell and gene therapy is witnessing an extraordinary revolution, bringing hope to patients with previously incurable diseases.

Read about it here:
bluecord.com/post/exciting-…

The field of cell and gene therapy is witnessing an extraordinary revolution, bringing hope to patients with previously incurable diseases. #CellandGeneTherapy #Diseases #3DPrinting #StemCell #CARTCells #Medicine 

Read about it here:
bluecord.com/post/exciting-…
account_circle